Literature DB >> 8422743

Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects.

J Shi1, N L Benowitz, C P Denaro, L B Sheiner.   

Abstract

We propose a parametric pharmacokinetic-pharmacodynamic model for caffeine that quantifies the development of tolerance to the pressor effect of the drug and characterizes the mean behavior and inter-individual variation of both pharmacokinetics and pressor effect. Our study in a small group of subjects indicates that acute tolerance develops to the pressor effect of caffeine and that both the pressor effect and tolerance occur after some time delay relative to changes in plasma caffeine concentration. The half-life of equilibration of effect with plasma caffeine concentration is about 20 minutes. The half-life of development and regression of tolerance is estimated to be about 1 hour, and the model suggests that tolerance, at its fullest, causes more than a 90% reduction of initial (nontolerant) effect. Whereas tolerance to the pressor effect of caffeine develops in habitual coffee drinkers, the pressor response is regained after relatively brief periods of abstinence. Because of the rapid development and regression of tolerance, the pressor response to caffeine depends on how much caffeine is consumed, the schedule of consumption, and the elimination half-life of caffeine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422743     DOI: 10.1038/clpt.1993.3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Central and peripheral effects of sustained caffeine use: tolerance is incomplete.

Authors:  Joanne Watson; Ian Deary; David Kerr
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

3.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

Review 4.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

Review 5.  Caffeine use in children: what we know, what we have left to learn, and why we should worry.

Authors:  Jennifer L Temple
Journal:  Neurosci Biobehav Rev       Date:  2009-01-20       Impact factor: 8.989

6.  The effects of caffeine on blood pressure and heart rate: A review.

Authors:  P J Green; R Kirby; J Suls
Journal:  Ann Behav Med       Date:  1996-09

Review 7.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

8.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

9.  The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers.

Authors:  P J Green; J Suls
Journal:  J Behav Med       Date:  1996-04

10.  Modelling the cardiovascular effects of ephedrine.

Authors:  Adam M Persky; N Seth Berry; Gary M Pollack; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.